Novo Nordisk Strengthens Obesity and Diabetes Portfolio with Akero Therapeutics Acquisition
Novo Nordisk announced that it has entered into a definitive agreement to acquire Akero Therapeutics, Inc. (Akero), a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need. Akero’s fibroblast growth factor 21 (FGF21) analo…
